Technical Analysis for DMTK - DermTech, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Boomer Sell Setup | Bearish Swing Setup | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | -4.14% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.14% | |
Spinning Top | Other | -4.14% | |
Narrow Range Bar | Range Contraction | -4.14% | |
Inside Day | Range Contraction | -4.14% | |
Wide Bands | Range Expansion | -4.14% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 20 hours ago |
Down 3% | about 20 hours ago |
Down 2 % | about 20 hours ago |
Down 1% | about 20 hours ago |
10 DMA Resistance | about 21 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/02/2024
DermTech, Inc. Description
DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Classification
Sector: Industrials
Industry: Conglomerates
Keywords: Medicine Cancer Melanoma Dermatology Gene Expression Diagnostic Tests Risk Assessment Pathology Biopsy Skin Cancer Assessment Products Melanoma Skin Cancer Pigmented Lesion Cutaneous Conditions Non Melanoma Skin Cancer
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.66 |
52 Week Low | 0.63 |
Average Volume | 373,419 |
200-Day Moving Average | 1.84 |
50-Day Moving Average | 1.17 |
20-Day Moving Average | 0.96 |
10-Day Moving Average | 0.71 |
Average True Range | 0.10 |
RSI (14) | 25.93 |
ADX | 33.95 |
+DI | 11.71 |
-DI | 30.13 |
Chandelier Exit (Long, 3 ATRs) | 1.11 |
Chandelier Exit (Short, 3 ATRs) | 0.92 |
Upper Bollinger Bands | 1.53 |
Lower Bollinger Band | 0.39 |
Percent B (%b) | 0.24 |
BandWidth | 118.87 |
MACD Line | -0.17 |
MACD Signal Line | -0.15 |
MACD Histogram | -0.0208 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.74 | ||||
Resistance 3 (R3) | 0.74 | 0.73 | 0.72 | ||
Resistance 2 (R2) | 0.73 | 0.71 | 0.72 | 0.72 | |
Resistance 1 (R1) | 0.69 | 0.70 | 0.69 | 0.69 | 0.72 |
Pivot Point | 0.68 | 0.68 | 0.67 | 0.67 | 0.68 |
Support 1 (S1) | 0.65 | 0.66 | 0.64 | 0.64 | 0.61 |
Support 2 (S2) | 0.63 | 0.65 | 0.63 | 0.61 | |
Support 3 (S3) | 0.60 | 0.63 | 0.60 | ||
Support 4 (S4) | 0.59 |